Short Interest in Clearmind Medicine Inc. (NASDAQ:CMND) Increases By 45.6%

Clearmind Medicine Inc. (NASDAQ:CMND) was the recipient of a significant increase in short interest during the month of October. As of October 31st, there was short interest totalling 316,600 shares, an increase of 45.6% from the October 15th total of 217,400 shares. Currently, 10.5% of the shares of the company are short sold. Based on an average daily volume of 377,300 shares, the short-interest ratio is currently 0.8 days.

Clearmind Medicine Price Performance

Shares of CMND stock traded down $0.13 on Friday, hitting $1.34. The company’s stock had a trading volume of 284,485 shares, compared to its average volume of 1,358,733. The company has a current ratio of 1.71, a quick ratio of 1.71 and a debt-to-equity ratio of 0.01. The stock’s 50 day moving average is $1.37 and its 200-day moving average is $1.36. Clearmind Medicine has a fifty-two week low of $0.92 and a fifty-two week high of $6.80.

Clearmind Medicine (NASDAQ:CMND) last released its quarterly earnings results on Monday, September 16th. The company reported ($0.59) EPS for the quarter.

Institutional Investors Weigh In On Clearmind Medicine

An institutional investor recently raised its position in Clearmind Medicine stock. AdvisorShares Investments LLC increased its position in Clearmind Medicine Inc. (NASDAQ:CMND) by 14.2% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 128,641 shares of the company’s stock after buying an additional 15,948 shares during the quarter. AdvisorShares Investments LLC owned 7.60% of Clearmind Medicine worth $214,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Hedge funds and other institutional investors own 96.05% of the company’s stock.

Clearmind Medicine Company Profile

Clearmind Medicine Inc, a clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems in Canada and internationally. It develops treatments for alcohol use disorders, mental health disorder, binge drinking, obesity and metabolic disorder, and eating disorders, as well as depression, binge eating, psychotherapy, and other addiction and binge behaviors.